EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: A COMPARISON OF THE CONSECUTIVE HOVON-100 AND H-146 STUDIES

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: A COMPARISON OF THE CONSECUTIVE HOVON-100 AND H-146 STUDIES

EHA Highlights 2024 Roundtable Discussions
Icon Chair Speaker

Chair

Dr. Jorge Cortes

Icon Chair Speaker

Panelists

Dr. Julie Bergeron
Dr. Aniket Bankar

This program has been made possible through unrestricted support from Astellas.

Studies/trials discussed:

  • HAVON 100:Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults. A prospective randomized trial.
  • BLINATUMOMAB ADDED TO PREPHASE AND CONSOLIDATION THERAPY IN NEWLY DIAGNOSED PRECURSOR B-ALL IN ADULTS. A PHASE II HOVON TRIAL
  • H-146: Blinatumomab added to prephase and consolidation therapy in precursor B-acute lymphoblastic leukemia in adults.
Tagged